Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 695–696 | Cite as

ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease

  • Brittany L. Murphy
  • Judy C. BougheyEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22(5):1408–15.CrossRefGoogle Scholar
  2. 2.
    Untch M, Konecny GE, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. Breast 2014;23(5):526–37.CrossRefGoogle Scholar
  3. 3.
    Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608-14; discussion 614–6.CrossRefGoogle Scholar
  4. 4.
    Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–8.CrossRefGoogle Scholar
  5. 5.
    Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment: the dawn of personalized medicine. Exp Cell Res. 2014;320(1):1–11.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryMayo ClinicRochesterUSA
  2. 2.The Robert D. and Patricia E. Kern Center for the Science of Health Care DeliveryMayo ClinicRochesterUSA

Personalised recommendations